IV Nurse Week 2026: Build a Reliable Infusion System

Why this matters now

Infusion therapy is an enterprise pathway, not a collection of isolated tasks

An intravenous therapy order sets several systems in motion. A clinician assesses the need and expected duration. Someone selects a device and insertion approach. A qualified professional establishes access. Pharmacy prepares or verifies therapy. A pump, tubing set, drug library, and electronic record must align. Nurses inspect the site and response over time. Infection prevention, supply chain, biomedical engineering, informatics, and quality teams influence the conditions around the work. When the patient transfers or goes home, the therapy plan, device status, supplies, education, monitoring, and next owner must move together.

Executives often see only fragments of this route. The infection dashboard may focus on central lines. Unit reports may track infiltrations or phlebitis using different definitions. Pharmacy may monitor drug-library use and pump alerts. Supply chain may measure device availability. Nursing education may track competency completion. Home infusion may see incomplete referrals or missing supplies. Each measure can be legitimate while the overall pathway remains invisible. IV Nurse Week creates a useful checkpoint for asking whether these fragments form one governable system.

The scale of preventable disruption is not trivial. A 2024 systematic review and meta-analysis included 69 studies and 478,586 peripheral intravenous catheters. It estimated that all-cause failure before treatment completion occurred in 36.4% of catheters. The pooled proportion of catheter-associated bloodstream infection was much lower, 0.028%, and local infection was 0.150%, but the authors emphasized that the enormous volume of peripheral catheters creates a meaningful absolute burden.⁷ These pooled estimates combine heterogeneous populations and definitions. They should not be treated as a forecast for one hospital. They do establish that routine access deserves system-level attention.

Central access carries a different risk profile. A 2024 systematic review of 130 studies estimated that 30.2 of every 1,000 patients treated with a central venous catheter for three days would experience at least one of four serious complications included in its composite outcome. The review also reported substantial heterogeneity and cautioned that meta-regression findings were associative rather than causal.¹⁰ The management implication is not that one device is universally preferable. It is that device necessity, therapy-device fit, insertion method, maintenance, surveillance, and timely removal belong in one decision architecture.

Reliable care also depends on language. A systematic review of midline and long peripheral catheters found frequent device misclassification and wide variation in diagnostic criteria and reporting methods.¹⁵ If sites use different labels, denominators, or failure definitions, executives cannot tell whether variation reflects care, documentation, case mix, or measurement. Standard definitions are therefore an operating control, not merely a research preference.

IV nurses and vascular access specialists can help connect this system because their work spans assessment, device selection, insertion, maintenance, education, troubleshooting, and escalation. Yet a specialist team cannot compensate indefinitely for unclear policy, fragmented data, unavailable supplies, incompatible technology, or ambiguous ownership. Recognition becomes credible when leaders strengthen the system around the expertise.

A better management model

Run infusion therapy as a closed-loop operating system

A policy describes expected practice. A closed-loop operating system repeatedly checks whether the right plan is being executed, detects variation, assigns a response, and learns from the outcome. For infusion therapy, that cycle begins before insertion and ends only when the device is removed or responsibility transfers with the patient. The future-state model below is an executive design, not a bedside procedure. Clinical teams must follow current standards, manufacturer instructions, approved organizational policy, scope-of-practice requirements, and individual clinical judgment.

Start with therapy intent, not a preferred device

The first control is a visible statement of need. Leaders should expect the clinical workflow to make the indication, anticipated duration, urgency, infusate characteristics, setting, patient factors, and feasible alternatives available to the person selecting access. A device request without that context can turn habit or availability into the decision rule. The executive role is not to prescribe clinical selection. It is to ensure that the organization has a current, accessible decision pathway and an escalation route for cases that do not fit it.

Comparisons between midlines and peripherally inserted central catheters illustrate why simple rules can mislead. A 2023 systematic review and meta-analysis found fewer patients with catheter-related bloodstream infection among midline users, but that association did not remain when risk was evaluated per catheter. It also found a higher risk of superficial venous thrombosis with midlines, while other thrombosis comparisons were not statistically significant.¹⁶ The included evidence was dominated by observational studies. The findings support careful tradeoff analysis, not a universal substitution policy.

Device taxonomies must be explicit. The review by Fabiani and colleagues showed that midline and long peripheral devices were frequently mislabeled, which can distort complication comparisons.¹⁵ A systemwide data dictionary should therefore state device type, length or category as locally adopted, insertion site, indication, dwell denominator, complication definitions, and removal reason. Without that foundation, a dashboard may create false confidence.

Make difficult access visible before repeated attempts

Organizations need a defined path for patients with difficult intravenous access. That path may include early identification, attempt limits, escalation criteria, ultrasound-capable clinicians, and specialist consultation. A 2023 meta-analysis of seven studies involving 994 adults and children with predicted difficult access found higher odds of first-attempt success with ultrasound guidance than with traditional technique. The pooled odds ratio was 3.07, although settings and populations varied and sensitivity analysis weakened one secondary outcome.¹⁷ Two 2024 reviews focused on nurse-performed ultrasound-guided access also reported improved success outcomes, while noting heterogeneity in training, populations, and study methods.^8,9

The operational lesson is not to send every insertion to ultrasound. It is to create a timely escalation path and a competency system that matches the technology. Leaders should monitor first-attempt success within defined difficult-access populations, number of attempts before escalation, time to functional access, delays to therapy, patient experience, complications, and specialist capacity. Measures should be stratified by setting and population to avoid comparing unlike cases.

Design the specialist-team role around risk and learning

A 2024 systematic review compared vascular access specialist teams with standard practice for insertion and prevention of device failure. The review supports potential benefits but also documents variability in team structures, comparators, outcomes, and evidence quality.⁵ Executives should not reduce the finding to a binary question of whether to have a team. A better question is what functions require concentrated expertise and how those functions connect to frontline capability.

A specialist model can include consultation for device selection, difficult-access escalation, selected insertions, surveillance rounds, competency assessment, product evaluation, data definition, event review, and education. The organization should define coverage, response expectations, authority, and out-of-hours pathways. It should also measure whether the model improves the intended outcomes without creating a bottleneck or deskilling unit teams.

Workforce conditions matter. A mixed-method study linked peripheral catheter quality with nursing culture and described barriers and facilitators to guideline adherence across hospital wards.¹³ A multicenter retrospective cohort also examined catheter failure in relation to staffing levels and care complexity.¹⁴ These observational designs do not prove that a staffing change will cause a particular outcome. They do justify reviewing workload, interruptions, access to expertise, supplies, local norms, and leadership response alongside technical compliance.

Connect pump technology to a human operating model

Smart-pump drug libraries and electronic record interoperability can reduce some manual discrepancies, but technology does not eliminate the need for verification, exception management, maintenance, and learning. A 2025 systematic literature review found a generally favorable direction for interoperability and medication-error reduction while also noting variation in study methods and outcomes.³ Executives should review conflicts of interest, implementation context, and local workflow before generalizing vendor-associated findings.

Governance should connect nursing, pharmacy, informatics, biomedical engineering, medication safety, and quality. The operating group needs a cadence for drug-library updates, pump availability, integration uptime, alert review, overrides, workarounds, education, downtime procedures, and corrective action. Alert counts alone are insufficient. The denominator, clinical context, and severity matter, and an override can represent either an unsafe workaround or an appropriate response to a poorly designed limit.

Evidence into operations

Use the evidence without overstating what it proves

The literature offers actionable signals, but it does not support a single universal device algorithm, team configuration, securement product, training program, or pump workflow. Studies vary in definitions, settings, patient populations, intervention components, denominators, and follow-up. Systematic reviews frequently report heterogeneity, and many implementation studies are observational or conducted within one organization. The appropriate executive response is to build a locally governed test, measure it transparently, and preserve the limits of the evidence.

What the newest University full-text evidence adds

A 2025 evidence update from the University of Phoenix research environment reinforces the need to manage access as a pathway. In a multicenter emergency-department analysis of 319,938 peripheral catheter placements, wait times differed after adjustment across demographic and clinical groups. The observational design does not establish why those differences occurred, but it makes equity and time to access appropriate review dimensions.¹⁹ A separate audit of 1,568 peripheral-catheter care episodes in three Australian emergency departments found gaps in patient partnership, insertion practice, ongoing assessment, and documentation.²⁰ Interviews with clinicians in two emergency departments identified stressful conditions, insufficient education, and absent feedback mechanisms as barriers to adherence, while recognizing suboptimal practice and valuing patient engagement supported change.²⁴ Together, these studies argue for segmented measures, reliable feedback, and workflow design rather than a compliance-only response.

Recent implementation studies also show why leaders should pair outcome measures with process and context. A one-hospital quality-improvement study involving 1,330 peripheral catheters reported phlebitis declining from 15.1% to 9.4% after an infection-prevention bundle, alongside improvements in dressing, connection, and documentation practices.²⁵ In a pediatric interrupted time-series study, 585 observations before and after implementation of the I-DECIDED assessment tool showed reductions in idle devices, substandard dressings, and complications, with improved patient and family awareness and documentation.²⁹ Neither study proves that the same intervention will produce the same magnitude elsewhere. Both support a closed loop that observes practice, acts, and checks whether gains persist.

Capability evidence remains promising and conditional. An out-of-hospital review of 16,241 nursing visits identified repeated insertion challenges and emphasized education, preparation, and practice consistency.²² A small intensive-care quality initiative trained five nurses who completed 76 ultrasound-guided placements with reported overall success within two attempts ranging from 70% to 90%.²³ A 2025 narrative review, a prospective pediatric cohort, and a qualitative study of hospital-based student training likewise support structured education and selective visualization technology while highlighting setting, learner, and patient differences.^26,28,30 The management control is therefore observed competency plus timely escalation, not technology acquisition alone.

Maintenance and high-risk infusion evidence calls for similar restraint. A scoping review of 39 studies found substantial variation and no clinical consensus on peripheral-catheter flushing technique, volume, or frequency.³² A computational fluid-dynamics simulation may inform education about pulsatile flushing, but it is not a patient-outcome trial.²⁷ A 2025 evidence summary synthesized guidance for peripheral vasopressor administration across training, site selection, placement, regimen, and complication management, while cautioning that institutional fit must be evaluated.³³ Two nursing practice articles also emphasize defined eligibility, monitoring, interprofessional coordination, and response to infiltration or extravasation.^21,31 Leaders should translate those domains through approved local policy and current clinical standards rather than use an article as a bedside protocol.

Measure education as a transfer-to-practice system

Competency cannot be established by attendance alone. A learning system should define the skill, supervised practice, validation method, renewal expectation, escalation boundary, and outcome signal. The 2025 training review found promising reductions in overall short peripheral catheter failure, but only three randomized trials met inclusion criteria and the interventions differed substantially.¹ That evidence supports structured training while leaving important questions about optimal content, duration, sustainability, and cost.

Quality-improvement evidence presents a similar pattern. Cho and Kim reviewed 27 studies involving ultrasound-guided placement, dressings, devices, and bundles. Improvements in patient outcomes and nursing capabilities were reported, but sustainability and spread were frequently underdeveloped.² An executive sponsor should therefore ask what will keep the practice reliable after the pilot team, educator time, or initial attention recedes.

Treat securement as an evidence question, not a brand decision

Securement affects movement, dislodgement, dressing integrity, skin injury, and the ability to inspect the site. Yet product comparisons do not consistently identify a universally superior option. A 2024 randomized study of 281 patients compared two dressing approaches and did not establish a clear overall advantage in the reported catheter course.¹¹ A 2023 three-group pilot randomized trial showed the feasibility of comparing securement bundles but was not designed to settle the question for all settings.¹⁸

Leaders should connect product evaluation to a standard protocol and balanced measures. These can include premature failure, dislodgement, occlusion, infiltration, phlebitis, skin injury, visibility, patient comfort, application time, waste, and total replacement burden. Procurement cost per dressing is not the same as cost per successfully completed therapy. Any local comparison should control definitions and document the population, inserter, site, dwell, and reason for removal.

Build a learning taxonomy before building a Pareto chart

A Pareto chart is useful only when categories are consistent and cases are coded reliably. Organizations should first define mutually understandable failure and delay categories, then review inter-rater agreement and missing data. Candidate categories include no longer indicated, infiltration or extravasation, occlusion, dislodgement, phlebitis, suspected infection, leaking, device malfunction, pump or tubing issue, supply delay, incomplete handoff, and unknown. The taxonomy must reflect current clinical definitions and should not force a complex event into one simplistic cause.

The evidence warns against premature ranking. Fabiani and colleagues found device misclassification and heterogeneous complication definitions.¹⁵ Marsh and colleagues also pooled studies with varying methods.⁷ A local Pareto analysis should therefore show the denominator, time period, inclusion rules, percentage of unknown cases, and whether categories represent observed failure modes or investigated causes.

Measurement

Build a scorecard that follows the whole infusion route

A useful executive scorecard is small enough to govern and detailed enough to trigger a response. It pairs leading process measures with outcomes, balancing measures, owners, and interpretive boundaries. It also separates device categories and care settings where the risks and denominators differ. A single enterprise failure rate can conceal important variation and encourage unproductive comparisons.

Specify the denominator before debating performance

Every metric needs a short specification: purpose, device category, population, inclusion and exclusion rules, numerator, denominator, data source, refresh cadence, owner, stratification, and known limitations. Failure per catheter, failure per 1,000 catheter-days, failure before therapy completion, and patients with at least one failure answer different questions. Combining them or changing the denominator across periods can create an apparent trend that does not reflect care.

The same discipline applies to central-line outcomes. The JAMA Internal Medicine review reported rates per 1,000 catheters for placement events and per 1,000 catheter-days for use-related complications.¹⁰ Executives should not place those values on one chart without making the denominators visible. Local dashboards should also distinguish surveillance definitions from clinically diagnosed events and retain the limits of small samples.

Use balancing measures to prevent local optimization

Reducing central-line utilization can be beneficial, but a poorly governed shift to peripheral or midline access can move complications rather than eliminate them. Raising first-attempt success can be useful, but funneling too many routine cases to a small specialist team can delay care. Tightening pump limits can reduce some risks while increasing alert burden and workarounds. A balanced scorecard should show treatment delay, replacement burden, specialist response time, patient experience, staff workload, supplies, and downstream escalation alongside the primary outcome.

Midline-versus-PICC evidence demonstrates the need for tradeoffs. The 2023 review reported a lower patient-level bloodstream infection association for midlines but a higher superficial thrombosis association, with important limitations in the underlying evidence.¹⁶ A leadership decision should therefore state the intended benefit, the balancing risks, the eligible population, and the stop or review criteria.

Execution

A 90-day roadmap for one closed infusion-reliability loop

The first 90 days should not attempt to replace every policy, product, pump, or device. The goal is to establish governance, define a trustworthy baseline, repair one high-risk break, and decide whether the method is ready to spread. A bounded pilot makes it possible to learn without claiming that an intervention proven in one unit will automatically work throughout the system.

Days 1–30: establish the foundation

Name the owners and decision rights. Appoint an executive sponsor with authority across clinical and enabling departments. Name one operational owner responsible for the weekly control loop. Form a small design group with nursing, vascular access or infusion expertise, pharmacy, infection prevention, informatics, biomedical engineering, supply chain, quality, analytics, and representatives from the pilot setting. Clarify who can change a device plan, escalate difficult access, pause an unsafe infusion process, resolve a pump or supply issue, and accept transition responsibility.

Map the route. Follow one representative therapy from order to completion. Capture the information, handoffs, systems, supplies, delays, workarounds, and decision points. Include transfers and after-hours conditions. Mark where the therapy intent or device status becomes unclear and where staff create parallel documentation to compensate. The map should distinguish policy from observed work.

Define the baseline. Select a small set of measures and write their specifications before comparing units or periods. Use the evidence to identify likely domains, but do not import pooled estimates as local targets. Review data quality and the percentage of events coded as unknown. If definitions are inconsistent, fixing the measurement system is part of the intervention.

Listen to staff and patients. Ask IV nurses, bedside nurses, pharmacists, vascular access specialists, patients, caregivers, and receiving services where the process creates repeated effort or uncertainty. The nursing-culture and staffing studies support looking beyond technical skill to workload, access to help, local norms, and leadership response.^13,14

Days 31–60: test one closed loop

Choose a bounded problem. Examples include delayed difficult-access escalation, inconsistent daily necessity review, repeated peripheral failure in one service, pump-library variance, or incomplete home-infusion handoff. Define the eligible population, current-state baseline, intervention, outcome, balancing measures, review frequency, and stop criteria. Avoid combining several major changes when the organization will not be able to tell which element mattered.

Build competency into the workflow. If the pilot includes ultrasound, device selection, securement, pump interoperability, or a new surveillance method, define who is trained, how competence is observed, when support is available, and how exceptions are handled. The training and quality-improvement reviews show promising outcomes but also limited trial counts and weak sustainability in many programs.^1,2

Run the review cadence. Hold a brief weekly review of the pathway measures, open risks, corrective actions, and staff feedback. Every signal should have an owner and due date. Separate immediate clinical response from system learning. A bedside concern may require urgent action, while the aggregate pattern may require policy, supply, technology, or staffing redesign.

Test the transition. For transfer or home infusion, require the minimum information set: therapy and indication, expected duration, device type and status, latest assessment, medication and pump information, supplies, monitoring, patient or caregiver education, unresolved risks, contact route, follow-up, and accountable receiving owner. Confirm receipt through the organization’s approved method rather than assuming that sending a document completed the handoff.

Days 61–90: decide what to standardize

Review outcomes with limitations intact. Compare the pilot with the prespecified baseline, examine balancing measures, and ask whether workload or delay moved elsewhere. A reduction in observed failures can reflect documentation changes, device mix, case mix, or shorter dwell. A rise in incident reports can reflect improved trust. Display missing data and unknown categories rather than excluding them silently.

Choose among expand, adapt, hold, or stop. The decision record should state the observed results, uncertainty, safety considerations, workforce and cost implications, and unresolved questions. If the pilot involved a product or vendor, include conflicts of interest and avoid allowing procurement savings to substitute for clinical and operational evaluation.

Report back during IV Nurse Week. Share what staff identified, what leaders changed, what remains open, and who owns the next action. Recognize clinical expertise by making the operating commitment visible. Connect the work with related resources on closed-loop medication systems, enterprise capacity and competency, and medication access, ownership, and continuity.